Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Neurological manifestations in Erdheim-Chester disease: Two case reports
Journal Information
Vol. 31. Issue 6.
Pages 426-428 (July - August 2016)
Vol. 31. Issue 6.
Pages 426-428 (July - August 2016)
Letter to the Editor
DOI: 10.1016/j.nrleng.2014.01.007
Full text access
Neurological manifestations in Erdheim-Chester disease: Two case reports
Manifestaciones neurológicas en la enfermedad de Erdheim-Chester: a propósito de 2 casos
I. Roucoa,
Corresponding author

Corresponding author.
, J. Arosteguib, A. Cánovasc, J. González del Tánagod, I. Fernándeze, J.J. Zarranza
a Servicio de Neurología, Hospital Universitario de Cruces, Osakidetza, Baracaldo, Vizcaya, Spain
b Servicio de Reumatología, Hospital Universitario de Cruces, Osakidetza, Baracaldo, Vizcaya, Spain
c Servicio de Medicina Interna, Hospital Universitario de Cruces, Osakidetza, Baracaldo, Vizcaya, Spain
d Servicio de Anatomía Patológica, Hospital Universitario de Cruces, Osakidetza, Baracaldo, Vizcaya, Spain
e Servicio de Medicina Nuclear, Hospital Universitario de Cruces, Osakidetza, Baracaldo, Vizcaya, Spain
Article information
Full Text
Download PDF
Figures (2)
Full Text
Dear Editor:

Erdheim-Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis characterised by multi-organ xanthogranulomatous infiltration of histiocytes (CD68+/CD1−). Two highly suggestive characteristics of this disease are sclerosis of the long bones and perirenal fat infiltration.1 The central nervous system (CNS) involvement occurs in 30% to 50% of cases and is the main predictor of a poor prognosis.1,2 High doses of interferon alfa have been proposed as first-line treatment in the case of CNS involvement.3,4 Alternative therapies are based on isolated cases reporting good clinical responses to such immunomodulatory drugs as imatinib5 (a potent tyrosine kinase inhibitor) and anakinra6 (a recombinant form of interleukin-1 receptor antagonist), or immunosuppressants such as cladribine.7 Recently, vemurafenib (a potent B-Raf enzyme inhibitor) has demonstrated efficacy on refractory patients with the BRAF V600E mutation.8

In this report we present 2 patients with ECD and neurological impairment, describe clinical and MRI findings, and characterise disease progression for each of the treatments employed.

Case 1

Our first patient was a 68-year-old man with a history of ischaemic heart disease and prostate cancer treated in 2008. He was admitted in June 2011 due to a 5-year history of osteosclerotic lesions; the initial biopsy was non-diagnostic (Fig. 1A). The patient presented progressive instability and dysarthria over the previous several months. The initial examination revealed pancerebellar syndrome; all other results were normal. Blood and CSF analysis results were within normal levels with the exception of an ESR of 56mm/h. A brain MRI scan showed a signal alteration in the pons that we interpreted as residual ischaemic gliotic changes. An abdominal CT scan disclosed bilateral perirenal mass infiltration (Fig. 1B); a biopsy showed a histiocytic infiltrate (Fig. 1C) with an immunohistochemical profile positive for CD68 and negative for CD1a and S100, findings that are compatible with ECD. The patient was treated with prednisone (1mg/kg/day) and interferon alfa (3-6million IU/day, subcutaneously, 3 times per week). After 6 months the treatment was discontinued due to progression of neurological symptoms, aggravation of the pancerebellar syndrome to the point that he was no longer able to walk, and development of pyramidal signs and behaviour disorders (Fig. 1D and E). Imatinib (400mg/d) and cladribine were ineffective. The patient, a carrier of the BRAF V600E mutation, started treatment with vemurafenib 2 months ago, with no clinical changes.

Figure 1.

(A) Simple radiography of the pelvis: osteosclerosis on the diaphysis and epiphysis of both femurs and the pubic bone. (B) Abdominal CT scan: infiltrating perirenal mass showing increased uptake. (C) Haematoxylin–eosin stain: histiocytic infiltrate with abundant clear to foamy cytoplasm. (D) Brain MRI, FLAIR axial sequence at 9 months: signal alterations in the pons and spreading towards the middle cerebellar peduncles. (E) 18F-FDG PET-CT scan: ring-shaped uptake pattern in the pons showing hypometabolic activity at the centre and moderate peripheral activity.

Case 2

The second patient was a 50-year-old woman with a long history of depression. In December 2010, she was diagnosed with central diabetes insipidus. An MRI scan showed hypothalamus and pituitary gland enlargement, bilateral parasellar masses, and signal alterations at the level of the brainstem and uncus (Fig. 2A and B). The neurological examination showed mild dysarthria; all other findings were normal. The results of the blood and CSF analyses were within normal limits, except for an ESR of 82mm/h. An abdominal CT scan revealed perirenal and peri-aortic abdominal infiltration, and bone scintigraphy showed foci of increased uptake in the diaphysis of the tibias and fibulas. A bone biopsy confirmed the diagnosis of ECD. A brain 18F-FDG-PET/CT scan displayed increased metabolic activity in the brain regions which showed thickening and contrast enhancement on MRI (Fig. 2C). Treatment with interferon alfa (3 million IU/day, 3 times per week, subcutaneously) was discontinued after 6 months due to intolerance and systemic disease progression. Anakinra and cladribine were ineffective and the patient developed cerebellar and pyramidal syndrome to the point of being bedridden; she died 2 years after diagnosis (Fig. 2D and E).

Figure 2.

(A) Brain MRI, FLAIR axial sequence: hyperintensities in the middle cerebellar peduncles, dorsal pons, mesencephalic periaqueductal grey, and uncus. (B) Brain MRI, T1-weighted axial sequence with gadolinium: contrast-enhanced bilateral parasellar lesions, larger on the right side, and in the torcula and bilateral tentorium cerebelli. (C) 18F-FDG PET/CT: increased uptake in the area of the pituitary gland and the torcula. (D) Brain MRI, FLAIR axial sequence at 18 months: signal alterations at the level of the middle cerebellar peduncles. (E) Brain MRI, T1-weighted axial sequence with gadolinium: nodular contrast enhancement at the level of the middle cerebellar peduncles.


Progressive cerebellar syndrome and pyramidal syndrome are the main neurological manifestations of ECD. Diffuse hyperintensities extending through the pons and middle cerebellar peduncles are characteristic of the disease, although several other neuroradiological patterns have been described.9,10 The correct diagnosis is difficult to make if the systemic disease is unknown. PET/CT with 18F-FDG is a useful tool in both the diagnosis and the evaluation of response to treatment.11 However, as observed in these 2 cases, not all brain lesions demonstrate the same behaviour. One possible explanation for these findings is the existence of a neurodegenerative pattern in addition to the mass infiltration, which could explain the progression of neurological impairment as well as the lack of response to treatment.12,13

J. Haroche, L. Arnaud, Z. Amoura.
Erdheim-Chester disease.
Curr Opin Rheumatol, 24 (2012), pp. 53-59
M. Juanós, A. Selva-O’Callaghan, J. Solanich, A. Vidaller-Palacin, S. Martí, J.M. Grau, et al.
Enfermedad de Erdheim-Chester: estudio de 12 casos.
Med Clín, 139 (2012), pp. 398-403
F. Braiteh, C. Boxrud, B. Esmaeli, R. Kurzrockv.
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferón-alpha.
Blood, 106 (2005), pp. 2992-2994
L. Arnaud, B. Hervier, A. Neel, M. Hamidou, J.E. Kahn, B. Wechsler, et al.
CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.
Blood, 117 (2011), pp. 2778-2782
F. Janku, H.M. Amin, D. Yang, I. Garrido-Laguna, J.C. Trent, R. Kurzrock.
Response of histiocytoses to imatinib mesylate: fire to ashes.
J Clin Oncol, 28 (2010), pp. 633-636
A. Aouba, S. Georgin-Lavialle, C. Pagnoux, N. Martin, A. Renand, F. Galateau-Salle, et al.
Rationale and efficacy of interleukin-1 in targeting in Erdheim-Chester disease.
Blood, 116 (2010), pp. 4070-4076
C. Myra, L. Sloper, P.J. Tighe, R.S. McIntosh, R.H.S. Gregson, M. Sokal, et al.
Treatment of Erdheim-Chester disease with cladribine: a rational approach.
Br J Ophthalmol, 88 (2004), pp. 844-847
J. Haroche, F. Cohen-Aubart, J.F. Emile, L. Arnaud, P. Maksud, F. Charlotte, et al.
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Blood, 121 (2013), pp. 1495-1500
F. Bianco, E. Iacovelli, E. Tinelli, N. Locuratolo, F. Pauri, F. Fattapposta.
Characteristic brain MRI appearance of Erdheim-Chester disease.
Neurology, 73 (2009), pp. 2120-2121
F. Lachenal, F. Cotton, H. Desmurs-Clavel, J. Haroche, H. Taillia, N. Magy, et al.
Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature.
J Neurol, 253 (2006), pp. 1267-1277
L. Arnaud, Z. Malek, F. Archambaud, A. Kas, D. Toledano, A. Drier, et al.
18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease.
Arthritis Rheum, 60 (2009), pp. 3128-3138
M.J. Ribeiro, A. Idbaih, C. Thomas, P. Remy, N. Martin-Duverneuil, Y. Samson, et al.
18F-FDG PET in neurodegenerative Langerhans cell histiocytosis: results and potential interest for an early diagnosis of the disease.
J Neurol, 255 (2008), pp. 575-580
A. Conley, S. Manjila, H. Guan, M. Guthikonda, W.J. Kupsky, S. Mittal.
Non-Langerhans cell histiocytosis with isolated CNS involvement: an unusual variant of Erdheim-Chester disease.
Neuropathology, 30 (2010), pp. 634-647

Please cite this article as: Rouco I, Arostegui J, Cánovas A, González del Tánago J, Fernández I, Zarranz JJ. Manifestaciones neurológicas en la enfermedad de Erdheim-Chester: a propósito de 2 casos. Neurología. 2016;31:426–428.

Copyright © 2013. Sociedad Española de Neurología
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.